Abstract
In the span of a season, a global cadre of researchers has leveraged years of drug development into a slew of possible treatments for severe acute respiratory syndrome (SARS). Since the beginning of the SARS outbreak last spring, large drug companies have dusted off libraries of failed antivirals, famous researchers have adapted the latest anti-HIV strategy, and federal agencies have busied themselves screening thousands of existing drugs.

This publication has 0 references indexed in Scilit: